

TARGETED GENETICS CORP /WA/

Form 8-K

March 18, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) March 17, 2004

**Targeted Genetics Corporation**

---

(Exact name of registrant as specified in charter)

Washington  
(State or other jurisdiction  
of incorporation)

0-23930  
(Commission  
File Number)

91-1549568  
(IRS Employer  
Identification No.)

1100 Olive Way, Suite 100, Seattle, Washington  
(Address of principal executive offices)

98101  
(Zip Code)

Registrant's telephone number, including area code (206) 623-7612

Not Applicable

---

(Former name or former address, if changed since last report)

1

---

**TABLE OF CONTENTS**

Item 5. Other Events.

Item 7. Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events.**

On March 17, 2004, Targeted Genetics Corporation issued a press release announcing its initiation of a Phase I clinical trial of its product candidate, tgAAC94, in patients with rheumatoid arthritis. A copy of the press release is furnished as Exhibit 99.1 and is incorporated into this current report by reference.

**Item 7. Exhibits.**

- (a) Financial statements of business acquired.

Not applicable.

- (b) Pro forma financial information.

Not applicable.

- (c) Exhibits.

**Exhibit  
No.**

**Description**

---

99.1	Press Release of Targeted Genetics Corporation dated March 17, 2004
------	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARGETED GENETICS CORPORATION

Date: March 17, 2004

By:         /s/ Todd E. Simpson        

Todd E. Simpson  
Vice President, Finance and Administration  
and Chief Financial Officer, Secretary and  
Treasurer (Principal Financial and Accounting  
Officer)

**Table of Contents**

EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Targeted Genetics Corporation dated March 17, 2004